CPA
HAE icon

Capital Performance Advisors’s Haemonetics HAE Stock Holding History

Capital Performance Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14
Closed -$1.13K – 1204
2024
Q3 		$1.13K Buy
+14
New +$1.13K ﹤0.01% 1849

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Capital Performance Advisors's HAE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 14 shares — an estimated $1.13K sold.

Capital Performance Advisors first reported a position in HAE in Q3 2024 and held it in 1 quarter. The position peaked at $1.13K in Q3 2024. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 14 Haemonetics shares in Q4 2024, an estimated $1.13K.
  • Capital Performance Advisors first reported a position in Haemonetics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Haemonetics position peaked at $1.13K in Q3 2024.
  • 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.